Ardelyx Inc (ARDX) (Q3 2026) Earnings Call Highlights: Revenue Climbs 19% as IBSRELA Shines

Ardelyx Inc (ARDX) reported a 19% revenue increase in Q3 2026, driven by its IBSRELA drug. CEO Michael Raab and CFO Sue Hohenleitner addressed prescription trends, payer negotiations, and the company's IBSRELA Pharmacy Network (IPN). They reaffirmed guidance, citing strong fundamentals and positive early indicators from a DTC campaign. The company also discussed its Phase 3 ACCEL trial for CIC and inventory dynamics for XPHOZAH.

Original reporting
Published Nov 4, 2026, 5:12 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 5:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ardelyx Inc (ARDX) (Q3 2026) Earnings Call Highlights: Revenue Climbs 19% as IBSRELA Shines — source image
Decision brief

The 30-second read

$ARDXNeutralLow
01

Why it matters

The call reaffirmed guidance and disclosed a slight improvement in gross-to-net, offering limited new material for price action.

02

Market read

Earnings call provides modest new data; unlikely to trigger large price moves.

03

What to watch

Potential future label expansion for IBSRELA into CIC could drive longer-term upside not reflected in the call.

Relevance 7/10Novelty 5/10Timing: after-hours earnings call

Background

Ardelyx discussed IBSRELA performance, pharmacy network dynamics, and gross-to-net metrics during its Q3 2026 earnings call.

Company-level read

Ticker impact

$ARDXNeutralMedium confidence
Context

Earnings call disclosed reaffirmed guidance and Q3 gross-to-net of 31.7%, a new data point for Ardelyx.

Expected impact

likely modest upside as investors price in stable outlook

Evidence & confidence

No major guidance change or surprise; the new gross-to-net figure is incremental and does not imply a sharp move.

Market effects

Provides a modest data point for the biotech/IBS therapeutic sector but no sector-wide catalyst.

Limited to US biotech investors; no broader regional effect.

Low global relevance; primarily impacts Ardelyx shareholders.

Counterpoint

If investors expect a guidance downgrade, the reaffirmation could be seen as a positive surprise.

Key entities

  • Ardelyx Inc

    Biopharma focused on kidney disease therapies.

Related articles

$ARDXMed

Ardelyx (ARDX) Q3 2026 Earnings Call Transcript

Ardelyx (ARDX) reported Q3 2026 revenue of $125.5M, up 19% YoY. IBSRELA revenue grew 23% to $96.3M, while XPHOZAH revenue rose 7% to $29.2M. The company reaffirmed its full-year guidance and expects profitability in 2027. Ardelyx has $285.3M in cash and is advancing its ACCEL Phase III trial for chronic idiopathic constipation.

$ARDXMedAI 8/10

What Ardelyx (ARDX) Said on Its Q3 Earnings Call

Ardelyx (ARDX) reported Q3 revenue of $29.2M for XPHOZAH, up 7% YoY. Paid prescriptions rose 22%, but demand was offset by customer buying patterns. The company maintained its full-year revenue outlook of $110M-$120M. Ardelyx also launched a direct-to-consumer ad campaign for IBSRELA, with 91% of patients expressing interest. R&D expenses increased to $25.2M, and the company reported a net loss of $700K. Ardelyx expects to reach profitability in 2027, with a gross profit margin exceeding 95%.

$ARDXMed

Ardelyx completes enrollment in constipation drug trial

Ardelyx Inc. (ARDX) completed enrollment in its Phase 3 ACCEL trial for IBSRELA (tenapanor) in treating chronic idiopathic constipation, ahead of schedule. Topline data is expected in the second half of 2027. IBSRELA is currently approved for irritable bowel syndrome with constipation in adults. The trial's primary endpoint is assessing the drug's durable efficacy in relieving constipation.